Olga Grishina

发表

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

J. Duyster, J. Finke, G. Ihorst, 2018, BMC Cancer.

Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial.

K. Döhner, R. Schlenk, H. Döhner, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma—a randomized phase III trial (MATRix)

J. Finke, E. Valk, E. Zucca, 2016, BMC Cancer.

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.

H. Einsele, M. Egger, C. Schmoor, 2009, The Lancet. Oncology.

Thiotepa–fludarabine–treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial

C. Schmoor, P. Dreger, G. Kobbe, 2022, Bone Marrow Transplantation.

Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma)

P. Tassone, N. Raje, J. Duyster, 2018, Haematologica.

Decitabine Induces Gene Derepression on Monosomic Chromosomes: In Vitro and In Vivo Effects in Adverse-Risk Cytogenetics AML

C. Plass, M. Lübbert, B. Grüning, 2020, Cancer Research.

Randomized Phase II Study of All-Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status

K. Döhner, R. Schlenk, H. Döhner, 2021, Blood.

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius.

H. Einsele, M. Egger, C. Schmoor, 2011, Blood.

Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial.

C. Schmoor, D. Heim, G. Socié, 2017, The Lancet. Haematology.

Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial.

H. Einsele, C. Schmoor, A. Zander, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Thiotepa–fludarabine–treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial

C. Schmoor, P. Dreger, G. Kobbe, 2022, Bone Marrow Transplantation.

High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma—a randomized phase III trial (MATRix)

J. Finke, E. Valk, E. Zucca, 2016, BMC Cancer.

Activity of Decitabine (DAC) Combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML: Subgroup Analysis of a Randomized 2x2 Phase II Trial

K. Döhner, R. Schlenk, H. Döhner, 2020 .